Maze Therapeutics Inc
MAZE45.030USD
+1.080+2.46%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
2.16BValor de mercado
PerdaP/L TTM
Mais detalhes de Maze Therapeutics Inc Empresa
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Informações de Maze Therapeutics Inc
Código da empresaMAZE
Nome da EmpresaMaze Therapeutics Inc
Data de listagemJan 31, 2025
CEOColoma (Jason V)
Número de funcionários125
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 31
Endereço171 Oyster Point Boulevard, Suite 300
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Telefone16508505070
Sitehttps://www.mazetx.com/
Código da empresaMAZE
Data de listagemJan 31, 2025
CEOColoma (Jason V)
Executivos da empresa Maze Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
+3.00%
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Ms. Courtney J. Phillips
Ms. Courtney J. Phillips
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
+3.00%
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Detalhamento da receita
FY2025Q3
FY2025Q2
FY2024
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: seg, 17 de nov
Atualizado em: seg, 17 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Third Rock Ventures, LLC
11.27%
Frazier Life Sciences Management, L.P.
9.49%
ARCH Venture Partners
8.56%
Deep Track Capital LP
8.21%
Alphabet, Inc.
5.01%
Outro
57.45%
Investidores
Investidores
Proporção
Third Rock Ventures, LLC
11.27%
Frazier Life Sciences Management, L.P.
9.49%
ARCH Venture Partners
8.56%
Deep Track Capital LP
8.21%
Alphabet, Inc.
5.01%
Outro
57.45%
Tipos de investidores
Investidores
Proporção
Venture Capital
35.70%
Hedge Fund
16.44%
Investment Advisor/Hedge Fund
13.22%
Private Equity
10.76%
Investment Advisor
9.98%
Individual Investor
1.88%
Family Office
1.00%
Research Firm
0.45%
Endowment Fund
0.19%
Outro
10.36%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
154
41.80M
86.88%
+1.94M
2025Q3
111
39.53M
83.57%
-194.63K
2025Q2
100
42.58M
97.22%
+13.88M
2025Q1
93
44.69M
102.04%
+15.27M
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Third Rock Ventures, LLC
5.42M
11.27%
-1.60M
-22.78%
Nov 04, 2025
Frazier Life Sciences Management, L.P.
4.57M
9.49%
-1.00
-0.00%
Sep 30, 2025
ARCH Venture Partners
4.12M
8.56%
--
--
Sep 30, 2025
Deep Track Capital LP
3.95M
8.21%
--
--
Sep 30, 2025
Alphabet, Inc.
2.41M
5.01%
--
--
Sep 30, 2025
Andreessen Horowitz
1.70M
3.54%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
1.33M
2.77%
+915.34K
+218.14%
Sep 30, 2025
Matrix Capital Management Company, LP
1.65M
3.44%
-832.50K
-33.49%
Sep 30, 2025
VR Adviser, LLC
1.23M
2.56%
+1.23M
--
Sep 30, 2025
Logos Global Management LP
1.23M
2.55%
+615.39K
+100.57%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
0.53%
ALPS Medical Breakthroughs ETF
0.39%
iShares Micro-Cap ETF
0.12%
iShares Russell 2000 Value ETF
0.04%
ProShares UltraPro Russell2000
0.03%
ProShares Hedge Replication ETF
0.03%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
Schwab U.S. Small-Cap ETF
0.02%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporção0.53%
ALPS Medical Breakthroughs ETF
Proporção0.39%
iShares Micro-Cap ETF
Proporção0.12%
iShares Russell 2000 Value ETF
Proporção0.04%
ProShares UltraPro Russell2000
Proporção0.03%
ProShares Hedge Replication ETF
Proporção0.03%
iShares Russell 2000 ETF
Proporção0.02%
Proshares Ultra Russell 2000
Proporção0.02%
Schwab U.S. Small-Cap ETF
Proporção0.02%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
